Background: Chronic kidney disease (CKD) is frequently complicated by arrhythmias, plausibly leading to the increased risk of sudden cardiac death in this population. However, little is known about the association between CKD and third-degree atrioventricular block (3AVB) and need for permanent pacing.
Objectives: This study aimed to investigate the association between CKD and 3AVB.
Methods: In a population-based nested case-control study, patients with 3AVB were identified between July 1995 and December 2018 using Danish administrative registries. Cases were risk set matched 1:5 with controls on sex and birth year. Multivariable Cox regression was used to analyze the association between CKD and 3AVB, with subsequent logistic regression analyses for computation of odds ratios for pacemaker implantation stratified by dialysis or nondialysis CKD.
Results: A total of 31,301 patients with 3AVB were identified and matched with 155,506 controls. The mean age was 74.7 ± 12 years, and 40.2% were female. A significant association was found between CKD and 3AVB after adjustment for comorbidities and potential atrioventricular node blocking agents (HR: 1.83; 95% CI: 1.73-1.93). In stratified analyses, the association was stronger in patients using dialysis compared with nondialysis patients (HR: 7.71; 95% CI: 5.84-10.18; vs HR: 1.73; 95% CI: 1.64-1.83). The odds of pacemaker implantation were lower for patients using dialysis (OR: 0.77; 95% CI: 0.60-0.98) but comparable between patients with nondialysis CKD (OR: 1.04; 95% CI: 0.96-1.12) and patients without CKD.
Conclusions: CKD was independently associated with a higher rate of 3AVB, especially for patients using dialysis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jacep.2024.10.007 | DOI Listing |
Theranostics
January 2025
Department of Nephrology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Chronic kidney disease (CKD) is a global public health issue, with vascular calcification (VC) being a common and deadly complication. Despite its prevalence, the underlying mechanisms of VC remain unclear. In this study, we aimed to investigate whether and how Otubain-2 (OTUB2) contributes to VC.
View Article and Find Full Text PDFJ Pharm Policy Pract
December 2024
College of Pharmacy and Health Sciences, Ajman University, Ajman, UAE.
Background: Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3-5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.
Methods: This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021.
Nephrology (Carlton)
January 2025
Division of Nephrology, School of Clinical Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Hong Kong SAR.
Prevention of end-stage kidney disease (ESKD) is a major objective in the management of patients with lupus nephritis (LN). Chronic kidney disease (CKD) of variable severity is common in these patients, but recent literature has mostly focused on novel immunosuppressive treatments for acute LN, while the data on CKD is relatively limited. This scoping review aims to summarise available data on the prevalence and risk factors for CKD in patients with LN.
View Article and Find Full Text PDFJ Nephrol
January 2025
Pharmacoepidemiology Unit, Department of Clinical Pharmacology, Amiens-Picardie University Medical Center, CHU Amiens-Picardie, Rond-Point du Professeur Christian Cabrol, 80054, Amiens Cedex, France.
Background: Hyperuricemia is a hallmark of gout and a suspected risk factor for the progression of chronic kidney disease (CKD). However, the impact of urate-lowering therapy on CKD progression is subject to debate. The objective of the present study was to describe the prevalence of inappropriate urate-lowering therapy prescriptions and evaluate the association between urate-lowering therapy prescription and the progression of kidney disease in patients with CKD.
View Article and Find Full Text PDFNat Rev Nephrol
January 2025
AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Diuretic drugs act on electrolyte transporters in the kidney to induce diuresis and are often used in chronic kidney disease (CKD), given that nephron loss creates a deficit in the ability to excrete dietary sodium, which promotes an increase in plasma volume. This rise in plasma volume is exacerbated by CKD-induced systemic and intra-renal activation of the renin-angiotensin-aldosterone-system, which further limits urinary sodium excretion. In the absence of a compensatory decrease in systemic vascular resistance, increases in plasma volume induced by sodium retention can manifest as a rise in systemic arterial blood pressure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!